2026 年至 2032 年慢性阻塞性肺病市场（按类型、治疗类型、最终用户和地区划分）

慢性阻塞性肺病市场评估－2026-2032

在全球范围内，慢性阻塞性肺病的盛行率不断上升，推动了慢性阻塞性肺病的蔓延。由于青少年烟草消费量的增加以及大众对学名药使用的认识不断提高，预计到 2024 年市场规模将超过 211.7 亿美元，到 2032 年将达到约 353 亿美元的估值。

此外，新兴国家医疗支出的增加也刺激了慢性阻塞性肺病的治疗。政府和大公司不断增加的研发投入使得市场在 2026 年至 2032 年期间的复合年增长率达到 7.28%。

慢性阻塞性肺病市场定义/概述

慢性阻塞性肺病(COPD)，也称为肺气肿或慢性支气管炎，是一种导致气流受限和呼吸问题的肺部疾病。症状包括咳嗽、呼吸困难、喘息和疲劳。常见原因包括吸烟和空气污染，患有 COPD 的人患其他健康问题的风险更高。慢性支气管炎会导致支气管发炎，进而导致支气管肿胀和黏液积聚，使支气管开口变窄，使空气更难进出肺部。肺气肿是肺部底部气囊（肺泡）被破坏的疾病，它就像一棵倒置的树，气管是树干，支气管是树枝，肺泡是树叶。

慢性阻塞性肺病(COPD) 的治疗重点是缓解症状、改善生活品质和减缓病情进展。治疗的主要内容包括使用支气管扩张剂（放鬆呼吸道肌肉并改善气流）、吸入性皮质类固醇（抑制发炎）以及组合吸入药物（增强疗效）。包括运动训练、营养建议和教育的肺部復健计画对于增强患者能力和改善功能至关重要。在严重的情况下，可能需要补充氧气治疗。此外，戒烟对于阻止疾病进展至关重要，而接种疫苗和定期监测可以帮助防止病情恶化并有效控制合併症。

COPD 治疗的未来可能集中在个人化医疗、先进的药物传输系统和创新治疗方法。主要趋势包括针对特定发炎途径的生技药品、用于肺组织修復的基因和再生疗法、远端医疗和远端监控等数位健康技术以及新的吸入器技术和药物製剂。这些进步旨在改善 COPD 患者的治疗效果和生活质量，并加强患者管理和治疗计划的依从性。

提高对慢性阻塞性肺病(COPD) 的认识将如何增加慢性阻塞性肺病的采用？

人们对慢性阻塞性肺病(COPD) 的认识日益加深，全球范围内的诊断和认知度也相应提高。提高医疗专业人员和公众的认识对于早期发现 COPD 至关重要，这样才能及时介入并制定更好的管理策略。因此，人们越来越需要改进诊断工具、更有效的治疗方法以及更好地了解和控制 COPD 的研究。这种不断变化的情况凸显了教育和积极主动的医疗保健倡议对于减少 COPD 对个人和医疗保健系统的影响的重要性，从而推动了市场成长。

全球慢性阻塞性肺病 (COPD) 盛行率的不断上升是一项重大的公共卫生挑战，部分原因是吸烟，而吸烟仍然是 COPD 的主要危险因素。全球成年人吸烟率的上升导致慢性阻塞性肺病的负担日益加重，凸显了全面戒烟计画和加强烟草控制的迫切需求。此外，职业暴露于污染物和室内空气污染进一步加剧了 COPD 的风险。透过监管政策和职场干预来解决这些环境因素对于限制 COPD 的发生和发展至关重要，从而改善受影响个人的生活品质并减轻医疗资源的负担。

肺量计、 电脑断层扫描和生物标记检测等诊断技术的进步显着改善了慢性阻塞性肺病(COPD) 的管理。这些技术可以实现更早的发现、个人化的治疗计划和更好的症状控制。此外，支气管扩张剂、皮质类固醇和生技药品等治疗方案也改善了 COPD 患者的生活品质。例如，2021年2月，赛诺菲和再生元製药启动了一项III期临床试验，以评估itepekimab在抑制戒烟者COPD急性加重方面的疗效和安全性，该试验计划于2024年7月完成。

用于治疗慢性阻塞性肺病（COPD）的药物副作用的增加是否会限制其采用？

用于治疗慢性阻塞性肺病(COPD) 的药物的副作用日益增加，严重阻碍了市场的成长。据美国国家生物技术资讯中心称，吸入类固醇等药物会导致口腔感染疾病、瘀伤和声音沙哑，妨碍患者的依从性并限制市场扩张。此外，使用这些药物的 COPD 患者更容易感染流感、感冒和肺炎等呼吸道感染疾病，这进一步使治疗复杂化并增加了医疗成本。

此外，COPD 的复杂性和患者对治疗反应的多变性使得药物开发尤为具有挑战性。第二阶段 TERRANOVA 和 GALATHEA 试验等临床试验往往难以证明其疗效和安全性，进一步阻碍了 COPD 市场的进步。药物研发的这种不确定性阻碍了投资并减缓了新治疗方法的推出。

开发新药面临许多挑战，包括临床试验的高失败率。例如，2019年5月，气喘治疗药物贝那利珠单抗未能降低中度至极重度 COPD 患者的 COPD 年发作率。这些挫折凸显了发现有效治疗方法的难度，限制了市场的成长前景。

与 COPD 相关的併发症，如忧郁症、心臟病、肺动脉高压和肺癌也对有效管理和市场成长构成了挑战。这些併发症的严重性需要采取综合治疗方法，但这通常成本高昂且耗费资源，从而限制了市场的成长。

目录

第一章 引言

• 市场定义
• 市场区隔
• 调查方法

第二章执行摘要

• 主要发现
• 市场概览
• 市集亮点

第三章市场概述

• 市场规模和成长潜力
• 市场趋势
• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析

第四章慢性阻塞性肺病市场（依类型）

• 慢性支气管炎
• 气肿

第五章慢性阻塞性肺病市场（依治疗类型）

• 药物
• 支气管扩张剂单药治疗
• 短效β-2促效剂（SABAS）
• 长效β-2促效剂（LABAS）
• 抗胆碱药物
• 抗发炎药物
• 口服和吸入性皮质类固醇
• 抗白三烯药物
• 外科手术
• 肺减容手术（LVRS）
• 肺移植、肺切除手术
• 其他的
• 氧气疗法

第六章慢性阻塞性肺病市场（依最终用户）

• 医院
• 居家医疗
• 诊所
• 其他的

第七章区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利
• 亚太地区
• 中国
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯聯合大公国

第八章市场动态

• 市场驱动因素
• 市场限制
• 市场机会
• COVID-19 市场影响

第九章 竞争态势

• 主要企业
• 市场占有率分析

第十章 公司简介

• AstraZeneca
• Boehringer Ingelheim
• GlaxoSmithKline（GSK）
• Novartis
• Merck & Co.
• Pfizer
• Teva Pharmaceuticals
• Sanofi
• Mylan
• Chiesi Farmaceutici
• Sunovion Pharmaceuticals
• Orion Corporation
• Cipla
• Reddy's Laboratories
• Vectura Group
• Circassia Pharmaceuticals
• Theravance Biopharma
• Verona Pharma
• Glenmark Pharmaceuticals
• Pulmatrix

第十一章 市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第十二章 附录

• 简称列表
• 来源和参考文献

Chronic Obstructive Pulmonary Disease Market Valuation - 2026-2032

Rising incidence of COPD among populations across the globe is propelling the adoption of chronic obstructive pulmonary disease. The increasing tobacco consumption among young people & rising public awareness of the usage of generic drugs is driving the market size surpass USD 21.17 Billion valued in 2024 to reach a valuation of around USD 35.3 Billion by 2032.

In addition to this, increasing expenditure on healthcare is giving services in emerging countries is spurring up the adoption of chronic obstructive pulmonary disease. Growing R&D investment by the government and large players is enabling the market grow at a CAGR of 7.28% from 2026 to 2032.

Chronic Obstructive Pulmonary Disease Market: Definition/ Overview

Chronic obstructive pulmonary disease (COPD), also known as emphysema or chronic bronchitis, is a lung disease causing restricted airflow and breathing issues. Symptoms include cough, difficulty breathing, wheezing, and tiredness. Common causes include smoking and air pollution, and those with COPD are at higher risk of other health issues. Chronic bronchitis causes inflammation of the bronchial tubes, causing swelling and the buildup of mucus, which narrows the tube's opening, making it difficult for air to enter and exit the lungs. Emphysema is the breakdown of air sacs (alveoli) at the bottom of the lung, similar to an upside-down tree with the windpipe as the trunk, bronchi as branches, and air sacs as leaves.

Chronic Obstructive Pulmonary Disease (COPD) treatment focuses on alleviating symptoms, improving quality of life, and slowing disease progression. Key components include bronchodilators to relax airway muscles and improve airflow, inhaled corticosteroids to reduce inflammation, and combination inhalers for enhanced efficacy. Pulmonary rehabilitation programs, encompassing exercise training, nutrition advice, and education, are crucial for patient empowerment and functional improvement. Supplemental oxygen therapy may be necessary for severe cases. Additionally, smoking cessation is vital to halt disease progression, while vaccinations and regular monitoring help prevent exacerbations and manage comorbidities effectively.

The future of COPD treatment will focus on personalized medicine, advanced drug delivery systems, and innovative therapies. Key trends include biologics targeting specific inflammatory pathways, gene therapy and regenerative medicine for lung tissue repair, digital health technologies like telemedicine and remote monitoring, and novel inhaler technologies and drug formulations. These advancements aim to improve outcomes and quality of life for COPD patients, enhancing patient management and adherence to treatment plans.

How will Rising Awareness of Chronic Obstructive Pulmonary Disease (COPD) Increase Adoption of Chronic Obstructive Pulmonary Disease?

Rising awareness of chronic obstructive pulmonary disease (COPD) continue to advance, there is a corresponding increase in the diagnosis and recognition of the condition globally. This heightened awareness among healthcare professionals and the public is crucial in identifying COPD at earlier stages, allowing for timely interventions and better management strategies. Consequently, there is a growing demand for improved diagnostic tools, more effective treatments, and increased research efforts aimed at understanding and combating COPD. This evolving landscape underscores the importance of education and proactive healthcare initiatives to mitigate the impact of COPD on individuals and healthcare systems, this is bolstering the growth of the market.

The rise in COPD cases globally presents a significant public health challenge, driven in part by factors such as tobacco smoking, which remains a leading risk factor for the disease. The increasing prevalence of adult smoking worldwide has contributed to a higher burden of COPD, highlighting the urgent need for comprehensive smoking cessation programs and stricter tobacco control measures. Additionally, occupational exposures to pollutants and indoor air pollution further exacerbate the risk of developing COPD. Addressing these environmental factors through regulatory policies and workplace interventions is crucial in reducing the incidence and progression of COPD, thereby improving the quality of life for affected individuals and lessening the strain on healthcare resources.

Advancements in diagnostic technologies like spirometry, CT scans, and biomarker testing have significantly improved the management of Chronic Obstructive Pulmonary Disease (COPD). These technologies enable early identification, personalized treatment plans, and improved symptom control. Additionally, therapeutic options like bronchodilators, corticosteroids, and biologic medicines have enhanced the quality of life for COPD patients. For instance, in February 2021, Sanofi and Regeneron Pharmaceuticals are conducting a Phase III clinical trial to evaluate the effectiveness and safety of itepekimab in reducing acute COPD exacerbations in former smokers, with the trial set to conclude in July 2024.

Will Rising Side Effects of Drugs Used in Treating Chronic Obstructive Pulmonary Disease (COPD) Restrain Its Application?

The rising side effects of drugs used in treating Chronic Obstructive Pulmonary Disease (COPD) significantly hinder market growth. According to the National Center for Biotechnology Information, medications such as inhaled steroids can cause oral infections, bruising, and hoarseness, which deter patient compliance and limit market expansion. Additionally, COPD patients on these medications are prone to respiratory infections like flu, colds, and pneumonia, further complicating their treatment and increasing healthcare costs.

Moreover, the complexity of COPD and the variability in patient response to treatments make drug development particularly challenging. Clinical trials, such as the Phase II TERRANOVA and GALATHEA studies, often struggle to demonstrate efficacy and safety, further impeding progress in the COPD market. This uncertainty in drug development discourages investment and slows the introduction of new therapies.

The development of new drugs for COPD is fraught with challenges, including high failure rates in clinical trials. For instance, in May 2019, benralizumab, an asthma drug, failed to reduce annual COPD exacerbation rates in patients with moderate to very severe COPD. Such setbacks highlight the difficulties in discovering effective treatments, limiting market growth prospects.

Complications associated with COPD, including depression, heart problems, high blood pressure in lung arteries, and lung cancer, also pose challenges to effective management and market growth. The severity of these complications necessitates comprehensive treatment approaches, which are often costly and resource-intensive, restraining market growth.

Category-Wise Acumens

Which Factors Contribute to the Dominance of Drugs Segment in Chronic Obstructive Pulmonary Disease Market?

The drugs segment dominates the chronic obstructive pulmonary disease (COPD) market, primarily due to the widespread use of bronchodilators. Bronchodilators, both short-acting and long-acting, hold a largest market share. They are crucial for managing COPD symptoms by relaxing airways and providing rapid relief from bronchospasms and exacerbations. The inhaled delivery method enhances patient compliance, making them a preferred choice for both patients and healthcare providers. As COPD progresses and lung function declines, bronchodilators become even more significant in managing symptoms and preventing exacerbations.

Corticosteroids are essential COPD drugs that reduce airway inflammation and mucus production. They are often used in combination with bronchodilators, particularly in severe COPD patients or those with frequent exacerbations. They help alleviate symptoms and improve lung function over time, but long-term use may have potential side effects, requiring careful healthcare management.

Phosphodiesterase type 4 (PDE4) inhibitors represent a newer addition to COPD treatment options. These medications work by reducing inflammation and relaxing the airways, similar to corticosteroids but through a different mechanism. PDE4 inhibitors are typically prescribed for patients with severe COPD and a history of exacerbations despite bronchodilator and corticosteroid therapy. Their role in managing COPD involves improving lung function and reducing exacerbation frequency, contributing to overall disease control and patient well-being.

The COPD market comprises various drug classes, including bronchodilators for immediate symptom relief, corticosteroids for inflammation management, and PDE4 inhibitors for symptom relief, each playing a crucial role in managing COPD symptoms and enhancing patient outcomes.

Which Factors Enhance the Use of Chronic Obstructive Pulmonary Disease in Hospitals?

Hospitals dominate the chronic obstructive pulmonary disease (COPD) market, with specialized departments like pulmonology and respiratory therapy, and advanced diagnostic capabilities like pulmonary function tests and imaging, ensuring accurate diagnosis and disease monitoring.

Hospitals offer a multidisciplinary approach to COPD management, involving pulmonologists, respiratory therapists, nurses, and rehabilitation specialists. They provide comprehensive care, addressing both medical and supportive needs. They offer a range of COPD treatments, including bronchodilators, corticosteroids, oxygen therapy, and surgical interventions. Hospitals also participate in clinical trials for innovative therapies.

Hospitals provide 24/7 emergency services, crucial for COPD patients experiencing sudden exacerbations or respiratory distress. This accessibility ensures prompt medical intervention and reduces morbidity and mortality associated with severe COPD complications.

Country/Region-wise Acumens

Will Rising Prevalence of COPD in North America Mature Chronic Obstructive Pulmonary Disease Market?

North America stands out as a dominant force in the global chronic obstructive pulmonary disease (COPD) market for several compelling reasons. The region boasts a high prevalence of COPD, attributed partly to historical smoking rates and environmental factors. This prevalence drives substantial demand for COPD treatments and healthcare services, making it a significant contributor to the market's size and growth.

North America benefits from advanced healthcare infrastructure and robust pharmaceutical industry capabilities. This infrastructure supports comprehensive diagnostic capabilities, including advanced imaging and pulmonary function tests, crucial for accurate COPD diagnosis and monitoring. Moreover, the region's strong research and development ecosystem fosters continuous innovation in COPD therapies, ensuring patients have access to cutting-edge treatments and medications.

Also, efforts to raise public awareness about public health and implement smoking cessation programs in countries such as the United States and Canada are aimed at reducing risk factors for COPD and improving early detection. These initiatives contribute to improved disease management and outcomes, further solidifying North America's position as a leader in the global COPD market.

Furthermore, healthcare policies and reimbursement frameworks in North America facilitate access to COPD treatments, including bronchodilators, corticosteroids, and biologics. This accessibility ensures that COPD patients receive timely and appropriate care, enhancing treatment adherence and overall health outcomes.

Will Increasing Air Pollution in Asia Pacific Drive the Growth of Chronic Obstructive Pulmonary Disease Market?

The Asia-Pacific region is expected to witness significant growth in the drugs segment of the chronic obstructive pulmonary disease (COPD) market during the forecast period due to the rising prevalence of COPD. Increasing air pollution and high smoking rates in countries like China and India contribute to a growing patient population, driving demand for effective treatments.

A rising prevalence of respiratory distress conditions is a major driver in the region. According to the World Health Organization (WHO), over 90% of COPD-related deaths occur in low and middle-income countries, highlighting the critical need for effective treatments in Asia-Pacific.

Moreover, the presence of a large aging population in the region, which is more susceptible to COPD, is fueling the demand for maintenance and rescue medications. This demographic trend is a key driver of market growth in the drugs segment.

Pharmaceutical companies are increasingly focusing on the Asia-Pacific market due to its high growth potential. Investments in local manufacturing and distribution networks, along with strategic partnerships, are expanding the availability and affordability of COPD drugs, thereby supporting market expansion in the region.

Competitive Landscape

The competitive landscape of the chronic obstructive pulmonary disease (COPD) market is characterized by intense competition and rapid innovation. Companies are focusing on developing advanced drug formulations and delivery systems to improve patient outcomes and adherence. Strategic collaborations, mergers, and acquisitions are common as firms aim to expand their market presence and leverage synergistic capabilities. Additionally, substantial investments in research and development, along with an emphasis on personalized medicine and biologics, are driving the evolution of treatment options, making the market highly dynamic and competitive. Some of the prominent players operating in the chronic obstructive pulmonary disease market include:

AstraZeneca

Boehringer Ingelheim

GlaxoSmithKline (GSK)

Novartis

Merck & Co.

Pfizer

Teva Pharmaceuticals

Sanofi

Mylan

Chiesi Farmaceutici

Sunovion Pharmaceuticals

Orion Corporation

Cipla

Reddy's Laboratories

Vectura Group

Circassia Pharmaceuticals

Theravance Biopharma

Verona Pharma

Glenmark Pharmaceuticals

Pulmatrix

Latest Developments

In January 2022, A phase 4 study comparing Yupelri (revefenacin) and Spiriva (tiotropium) in improving lung health in adults with severe chronic obstructive pulmonary disease (COPD) is underway. The study assesses the safety of these two approved daily COPD maintenance treatments. Yupelri, a bronchodilator developed by Theravance Biopharma and Mylan, relaxes and widens lung airways, making breathing easier. It is available as an inhalable solution via a nebulizer.

In November 2021, AstraZeneca sold the rights to commercialize Tudorza (Eklira) and Duaklir to Swiss pharmaceutical business Covis Pharma Group for US$ 270 million. The products are intended for the treatment of chronic obstructive pulmonary disease (COPD).

Chronic Obstructive Pulmonary Disease Market, By Category

• Type:
• Chronic Bronchitis
• Emphysema
• Treatment Type:
• Drugs
• Bronchodilator Monotherapy
• Short-Acting Beta2-Agonists (SABAS)
• Long-Acting Beta2-Agonists (LABAS)
• Anti-Cholinergic Agents
• Anti-Inflammatory Drugs
• Oral And Inhaled Corticosteroids
• Anti-Leukotrienes
• Surgery
• Lung Volume Reduction Surgery (LVRS)
• Lung Transplant, Bullectomy
• Others
• Oxygen Therapy
• End-User:
• Hospitals
• Homecare Settings
• Clinics
• Others
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Chronic Obstructive Pulmonary Disease Market, By Type

• Chronic Bronchitis
• Emphysema

5. Chronic Obstructive Pulmonary Disease Market, By Treatment Type

• Drugs
• Bronchodilator Monotherapy
• Short-Acting Beta2-Agonists (SABAS)
• Long-Acting Beta2-Agonists (LABAS)
• Anti-Cholinergic Agents
• Anti-Inflammatory Drugs
• Oral And Inhaled Corticosteroids
• Anti-Leukotrienes
• Surgery
• Lung Volume Reduction Surgery (LVRS)
• Lung Transplant, Bullectomy
• Others
• Oxygen Therapy

6. Chronic Obstructive Pulmonary Disease Market, By End User

• Hospitals
• Homecare Settings
• Clinics
• Others

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• AstraZeneca
• Boehringer Ingelheim
• GlaxoSmithKline (GSK)
• Novartis
• Merck & Co.
• Pfizer
• Teva Pharmaceuticals
• Sanofi
• Mylan
• Chiesi Farmaceutici
• Sunovion Pharmaceuticals
• Orion Corporation
• Cipla
• Reddy's Laboratories
• Vectura Group
• Circassia Pharmaceuticals
• Theravance Biopharma
• Verona Pharma
• Glenmark Pharmaceuticals
• Pulmatrix

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References